Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden

Abstract Background Pathological complete response (pathCR) in rectal cancer is beneficial, as up to 75% of patients do not experience regrowth of the primary tumour, but it is poorly understood. We hypothesised that the changes seen in the pre-treatment biopsies of pathCR but not seen in residual t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Joanne D. Stockton, Louise Tee, Celina Whalley, Jonathan James, Mark Dilworth, Rachel Wheat, Thomas Nieto, S-CORT Consortium, Ian Geh, João D. Barros-Silva, Andrew D. Beggs
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2021-07-01
Col·lecció:	Radiation Oncology
Accés en línia:	https://doi.org/10.1186/s13014-021-01853-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!